BIOMAT Database Logo BIOMAT Database Logo

Dianhydrogalactitol (NSC-132313): phase II study in solid tumors. 1979

R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003961 Dianhydrogalactitol One of the cytotoxic dihalohexitols that alkylates and cross-links DNA via an epoxide group during all phases of the cell cycle, resulting in a disruption of DNA function and cell cycle arrest. It has antineoplastic activity and also causes bone marrow toxicity. Dianhydrodulcitol,Diepoxydulcitol,Diepoxygalactitol,1,2,5,6-Dianhydrogalactitol,1,2-5,6-Dianhydrogalactitol,NSC-132313,NSC 132313,NSC132313
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Phase I evaluation of dianhydrogalactitol (NSC-132313).
May 1976, Cancer treatment reports,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Survival and phase sensitivity of HeLa cells treated with dianhydrogalactitol (NSC-132313).
January 1975, Cancer chemotherapy reports,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
January 1976, Journal of the National Cancer Institute,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
A preliminary Pharmacokinetic study of dianhydrogalactitol (NSC-132313) disposition in the dog.
May 1977, Journal of the National Cancer Institute,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
October 1972, Cancer chemotherapy reports,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors.
March 1976, Journal of the National Cancer Institute,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Phase II study of carbestrol (NSC-19962) in patients with solid tumors.
October 1972, Cancer chemotherapy reports,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Phase II study of emetine (NSC-33669) in the treatment of solid tumors.
January 1973, Cancer chemotherapy reports,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
January 1979, Medical and pediatric oncology,
R de Jager, and A Brugarolas, and H Hansen, and F Cavalli, and H Ryssel, and P Siegenthaler, and A Clarysse, and J Renard, and Y Kenis, and P Alberto
Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa.
January 1983, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!